# Physiological Regulation of Nutritional and Metabolic Biomarkers in Obesity: Implications for Precision Nutrition

**Authors:** Girolamo Di Maio, Maria Giovanna Tafuri, Maria Casillo, Antonietta Messina, Salvatore Allocca, Ines Villano, Fiorenzo Moscatelli, Antonietta Monda, Marco La Marra, Vincenzo Monda

PMC · DOI: 10.3390/nu18061014 · Nutrients · 2026-03-23

## TL;DR

This paper reviews biomarkers in obesity to improve personalized nutrition strategies by identifying metabolic risks and dietary influences.

## Contribution

The paper systematically evaluates biomarkers and their modulation by diet for precision nutrition in obesity.

## Key findings

- Elevated CRP, reduced adiponectin, and increased HOMA-IR are key biomarkers for metabolic risk in obesity.
- Dietary factors like fatty acids and fiber influence biomarker profiles and metabolic outcomes.
- Multi-biomarker panels combined with clinical data can enable individualized nutrition strategies.

## Abstract

Obesity represents a heterogeneous metabolic disorder characterized by substantial interindividual variation in inflammatory status, insulin sensitivity, and cardiometabolic risk. Traditional anthropometric measures fail to capture this metabolic diversity, limiting risk stratification and personalized intervention strategies. This review critically examines nutritional and metabolic biomarkers that reflect the physiological dysregulation underlying obesity, including adipokines (leptin, adiponectin, resistin), inflammatory markers (C-reactive protein, interleukin-6, TNF-α), insulin resistance indices (HOMA-IR, fasting insulin, HbA1c), and lipid metabolism indicators (LDL cholesterol, triglycerides, HDL cholesterol, and liver enzymes such as ALT and GGT). Among these, elevated CRP, reduced adiponectin, and increased HOMA-IR have demonstrated the strongest clinical utility for early metabolic risk identification. We further evaluate emerging biomarkers—including circulating microRNAs, gut microbiota-derived metabolites (short-chain fatty acids, TMAO, lipopolysaccharides), and bile acid profiles—which offer additional mechanistic insight into diet–microbiome–host interactions. We systematically assess the mechanistic basis, clinical relevance, and nutritional modulation of each biomarker class, emphasizing how dietary composition—particularly fatty acid quality, fiber intake, and overall dietary patterns such as the Mediterranean diet—influences biomarker profiles and metabolic outcomes. Furthermore, we explore how biomarker-based phenotyping enables precision nutrition approaches by identifying individuals most likely to benefit from specific dietary interventions. Integration of multi-biomarker panels with clinical and genetic data holds promise for advancing from population-based dietary guidelines toward individualized nutrition strategies that optimize metabolic health and prevent obesity-related complications. Future research should prioritize validating biomarker-guided intervention frameworks, establishing standardized thresholds across diverse populations, and developing clinically implementable tools for personalized nutritional medicine.

## Linked entities

- **Proteins:** lepa (leptin a), LOC114022543 (uncharacterized LOC114022543), IL6 (interleukin 6), TNF (tumor necrosis factor), GPT (glutamic--pyruvic transaminase), GGT1 (gamma-glutamyltransferase 1)
- **Chemicals:** TMAO (PubChem CID 1145)
- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** inflammatory (MESH:D007249), Obesity (MESH:D009765), insulin resistance (MESH:D007333), metabolic disorder (MESH:D008659)
- **Chemicals:** short-chain fatty acids (MESH:D005232), triglycerides (MESH:D014280), lipid (MESH:D008055), lipopolysaccharides (MESH:D008070), TMAO (MESH:C005855), fatty acid (MESH:D005227), bile acid (MESH:D001647), cholesterol (MESH:D002784)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13029434/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13029434/full.md

## References

133 references — full list in the complete paper: https://tomesphere.com/paper/PMC13029434/full.md

---
Source: https://tomesphere.com/paper/PMC13029434